This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Given Imaging Announces The Results Of Two Recent Studies Underscoring The Economic Value And Clinical Utility Of PillCam(R) ESO In Managing Upper GI Bleeding In The Emergency Department Setting

- Cost analysis shows PillCam ESO saves more than $10,000 versus a scoring-based risk stratification strategy for patients at low risk -

- PillCam ESO is significantly more effective than nasogastric tubes in detecting upper GI bleeding and comparable to EGD in identifying upper GI ulcerations -

SEATTLE, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Given Imaging Ltd, (Nasdaq:GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced results from two studies highlighting the clinical and economic benefits of PillCam ESO in the evaluation of patients with acute upper gastrointestinal (GI) bleeding in the emergency department setting. Both studies were presented during the American College of Emergency Physicians (ACEP) Scientific Assembly, the largest annual international emergency medicine conference, which took place in Seattle, Washington, October 14-17, 2013.

"The Cost-Effectiveness Analysis of Video Capsule Endoscopy Compared to Other Strategies to Manage Acute Upper Gastrointestinal Hemorrhage in the Emergency Department " (poster 65), presented by Andrew Meltzer, M.D., George Washington University Medical Center, Washington, DC and colleagues, analyzed the cost variances among diagnostic strategies including PillCam capsule endoscopy, risk stratification using the Glasgow-Blatchford score, nasogastric tube placement and an admit-all strategy. They found that, for patients at low risk of requiring endoscopic hemostatic intervention, capsule endoscopy was the dominant strategy with a cost of $5,691. These metrics were significantly stronger than all of the remaining strategies including the nasogastric tube strategy with added incremental cost of $2,469, the risk stratification strategy with an incremental cost of $10,695 and the admit-all strategy with an incremental cost of $17,076 versus capsule endoscopy. For moderate risk patients, capsule dominated an admit-all strategy with a cost of $9,190 versus an added incremental admit-all cost of $13,098. Based on this analysis, researchers concluded that capsule endoscopy may be cost-effective for low and moderate risk patients presenting with upper GI bleeding to the emergency department.

Although the risk stratification strategy utilizing the Glasgow-Blatchford score is recommended, neither this strategy nor the nasogastric tube are utilized by most emergency departments. A 2012 National Institute of Health funded study found that one in every five Americans has at least one visit to the emergency department per year 1 , with a large number of patients depending on the emergency department to obtain acute medical care, resulting in increased healthcare costs.

"PillCam's unique ability to directly visualize the upper GI tract non-invasively to identify the presence or absence of a hemorrhage could offer a novel and cost-effective approach in the emergency department setting," said Dr. Meltzer. "The cost savings on a per-patient basis could have a positive impact on the economic outcomes health care systems are striving for today."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,274.93 -10.81 -0.06%
S&P 500 2,129.38 -1.44 -0.07%
NASDAQ 5,097.9440 +7.15 0.14%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs